Attention! Your ePaper is waiting for publication!
By publishing your document, the content will be optimally indexed by Google via AI and sorted into the right category for over 500 million ePaper readers on YUMPU.
This will ensure high visibility and many readers!
Your ePaper is now published and live on YUMPU!
You can find your publication here:
Share your interactive ePaper on all platforms and on your website with our embed function
Pharmaceutical Manufacturing Handbook: Production and
Pharmaceutical Manufacturing Handbook: Production and
Pharmaceutical Manufacturing Handbook: Production and
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
PHARMACEUTICAL MANUFACTURING HANDBOOK <strong>Production</strong> <strong>and</strong> Processes SHAYNE COX GAD, PH.D., D.A.B.T. Gad Consulting Services Cary, North Carolina A JOHN WILEY & SONS, INC., PUBLICATION
- Page 1: PHARMACEUTICAL MANUFACTURING HANDBO
- Page 6 and 7: Copyright © 2008 by John Wiley & S
- Page 8 and 9: vi CONTRIBUTORS Robert D. Arnold, T
- Page 10 and 11: viii CONTRIBUTORS Iv á n Pe ñ uel
- Page 12 and 13: x CONTENTS 3.2 Packaging and Labeli
- Page 15: PREFACE This Handbook of Manufactur
- Page 19 and 20: 1.1 BIOTECHNOLOGY - DERIVED DRUG PR
- Page 21 and 22: INTRODUCTION 5 provide a suffi cien
- Page 23 and 24: therapeutic potency, specifi city,
- Page 25 and 26: Diffi culties in peroral delivery h
- Page 27 and 28: tial. Therefore, the indication and
- Page 29 and 30: TABLE 2 Continued Parameter Assesse
- Page 31 and 32: ceutical stability program should a
- Page 33 and 34: FORMULATION DEVELOPMENT 17 see when
- Page 35 and 36: FORMULATION DEVELOPMENT 19 heat ter
- Page 37 and 38: organisms, stability (shelf life),
- Page 39 and 40: TABLE 3 Potential Degradative Mecha
- Page 41 and 42: QUALITY BY DESIGN AND SCALE-UP 25 w
- Page 43 and 44: QUALITY BY DESIGN AND SCALE-UP 27 p
- Page 45 and 46: ACKNOWLEDGMENTS The authors would l
- Page 47 and 48: REFERENCES 31 37. Berglund , M. , B
- Page 49 and 50: 1.2 REGULATORY CONSIDERATIONS IN AP
- Page 51 and 52: HISTORY OF BIOLOGICS REGULATION IN
- Page 53 and 54: HISTORY OF BIOLOGICS REGULATION IN
- Page 55 and 56:
HISTORY OF BIOLOGICS REGULATION IN
- Page 57 and 58:
TABLE 4 FDA Center Regulatory Respo
- Page 59 and 60:
approved via a BLA under the PHSA a
- Page 61 and 62:
LEGAL ARGUMENTS RELATED TO FOLLOW-O
- Page 63 and 64:
SCIENTIFIC ISSUES RELATED TO FOLLOW
- Page 65 and 66:
SCIENTIFIC ISSUES RELATED TO FOLLOW
- Page 67 and 68:
albumin with polysorbate 80 and gly
- Page 69 and 70:
PROPOSED REGULATORY PARADIGM: CASE
- Page 71 and 72:
effi cacy for Genotropin. These dat
- Page 73:
REFERENCES 57 21. Webber , K. ( 200
- Page 76 and 77:
60 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 78 and 79:
62 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 80 and 81:
64 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 82 and 83:
66 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 84 and 85:
68 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 86 and 87:
70 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 88 and 89:
72 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 90 and 91:
74 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 92 and 93:
76 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 94 and 95:
78 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 96 and 97:
80 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 98 and 99:
82 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 100 and 101:
84 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 102 and 103:
86 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 104 and 105:
88 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 106 and 107:
90 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 108 and 109:
92 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 110 and 111:
94 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 112 and 113:
96 RADIOPHARMACEUTICAL MANUFACTURIN
- Page 115 and 116:
2.1 STERILE PRODUCT MANUFACTURING J
- Page 117 and 118:
(FDA) in its 2004 Guideline on Ster
- Page 119 and 120:
PROCESS SELECTION AND DESIGN 103 di
- Page 121 and 122:
FACILITY DESIGN 105 is transfer int
- Page 123 and 124:
FACILITY DESIGN 107 The formulation
- Page 125 and 126:
FACILITY DESIGN 109 In large operat
- Page 127 and 128:
FACILITY DESIGN 111 universal expec
- Page 129 and 130:
FACILITY DESIGN 113 facilities equi
- Page 131 and 132:
from manual compounding of small ba
- Page 133 and 134:
2.1.5.4 Other Utilities The operati
- Page 135 and 136:
STERILIZATION AND DEPYROGENATION 11
- Page 137 and 138:
ENVIRONMENTAL CONTROL AND MONITORIN
- Page 139 and 140:
ENVIRONMENTAL CONTROL AND MONITORIN
- Page 141 and 142:
PRODUCTION ACTIVITIES 125 It is inc
- Page 143 and 144:
PRODUCTION ACTIVITIES 127 Filling o
- Page 145 and 146:
assembly/technique) using a growth
- Page 147 and 148:
culminate in the incubation of the
- Page 149 and 150:
REFERENCES REFERENCES 133 1. U.S. F
- Page 151:
ADDITIONAL READINGS 135 Ljungvist ,
- Page 155 and 156:
3.1 FROM PILOT PLANT TO MANUFACTURI
- Page 157 and 158:
BACKGROUND 141 Pisano [3] discusses
- Page 159 and 160:
T amb F3 F2 F1 Scale Scale Scale Ad
- Page 161 and 162:
LABORATORY VESSELS AND REACTION CAL
- Page 163 and 164:
LABORATORY VESSELS AND REACTION CAL
- Page 165 and 166:
Drive nozzle face D FIGURE 4 C E 10
- Page 167 and 168:
Overall U, English units 80 70 60 5
- Page 169 and 170:
mCp/UA, min 28 27 26 25 24 23 22 21
- Page 171 and 172:
control valve was on the inlet stre
- Page 173 and 174:
3.1.6 SUMMARY In this chapter we ha
- Page 175 and 176:
3.2 PACKAGING AND LABELING Maria In
- Page 177 and 178:
PACKAGING MATERIALS 161 For these r
- Page 179 and 180:
PACKAGING MATERIALS 163 3.2.2.2 Gla
- Page 181 and 182:
PACKAGING MATERIALS 165 Rubber clos
- Page 183 and 184:
PACKAGING MATERIALS 167 of the USP
- Page 185 and 186:
PACKAGING MATERIALS 169 Topical del
- Page 187 and 188:
PACKAGING MATERIALS 171 based topic
- Page 189 and 190:
QUALITY CONTROL OF PACKAGING MATERI
- Page 191 and 192:
QUALITY CONTROL OF PACKAGING MATERI
- Page 193 and 194:
TABLE 5 Chapter U.S. Pharmacopeia G
- Page 195 and 196:
QUALITY CONTROL OF PACKAGING MATERI
- Page 197 and 198:
Topical Drug Products Topical dosag
- Page 199 and 200:
IMPORTANCE OF PROPER PACKAGING AND
- Page 201 and 202:
4. Require that vials containing me
- Page 203 and 204:
8. A description of the scientifi c
- Page 205 and 206:
The only warning that is necessary,
- Page 207 and 208:
REGULATORY ASPECTS 191 Section 1451
- Page 209 and 210:
include any term qualifying a unit
- Page 211 and 212:
for the promulgation of any such re
- Page 213 and 214:
Label Issuance and Control • Acce
- Page 215 and 216:
REFERENCES 199 9. Aspinall , J. A.
- Page 217 and 218:
3.3 CLEAN - FACILITY DESIGN, CONSTR
- Page 219 and 220:
PLANNING FOR PROJECT SUCCESS 203 im
- Page 221 and 222:
PLANNING FOR PROJECT SUCCESS 205 of
- Page 223 and 224:
DESIGN OPTIONS 207 with clean - roo
- Page 225 and 226:
TABLE 1 Room Grade f A g B C D E An
- Page 227 and 228:
Clean Garment Storage Bench Air loc
- Page 229 and 230:
DESIGN OPTIONS 213 FIGURE 4 Furnish
- Page 231 and 232:
DESIGN OPTIONS 215 FIGURE 6 A CMU w
- Page 233 and 234:
DESIGN OPTIONS 217 spaces to suppor
- Page 235 and 236:
DESIGN OPTIONS 219 FIGURE 12 The wa
- Page 237 and 238:
DESIGN OPTIONS 221 FIGURE 15 Severa
- Page 239 and 240:
to the facility. IEST - RP - CC006
- Page 241 and 242:
CONSTRUCTION PHASE: CLEAN BUILD PRO
- Page 243 and 244:
APPENDIX A 227 and storage space fo
- Page 245 and 246:
APPENDIX A 229 closed at the neck,
- Page 247 and 248:
I. The HEPA fi lter protective fi l
- Page 249:
SECTION 4 NORMAL DOSAGE FORMS
- Page 252 and 253:
236 SOLID DOSAGE FORMS 4.1.9 Chewab
- Page 254 and 255:
238 SOLID DOSAGE FORMS A dose solub
- Page 256 and 257:
240 SOLID DOSAGE FORMS TABLE 3 Exci
- Page 258 and 259:
242 SOLID DOSAGE FORMS Antiadherent
- Page 260 and 261:
244 SOLID DOSAGE FORMS Despite the
- Page 262 and 263:
246 SOLID DOSAGE FORMS TABLE 4 Poly
- Page 264 and 265:
248 SOLID DOSAGE FORMS TABLE 5 Caps
- Page 266 and 267:
250 SOLID DOSAGE FORMS of both. Sof
- Page 268 and 269:
252 SOLID DOSAGE FORMS reaction in
- Page 270 and 271:
254 SOLID DOSAGE FORMS to a rapid o
- Page 272 and 273:
256 SOLID DOSAGE FORMS TABLE 8 Typi
- Page 274 and 275:
258 SOLID DOSAGE FORMS Piston Base
- Page 276 and 277:
260 SOLID DOSAGE FORMS TABLE 10 Exa
- Page 278 and 279:
262 SOLID DOSAGE FORMS pressures du
- Page 280 and 281:
264 SOLID DOSAGE FORMS 12. The Unit
- Page 283 and 284:
4.2 SEMISOLID DOSAGES: OINTMENTS, C
- Page 285 and 286:
OINTMENTS AND CREAMS 269 bases), ab
- Page 287 and 288:
OINTMENTS AND CREAMS 271 compendial
- Page 289 and 290:
TABLE 2 Properties of Different Gra
- Page 291 and 292:
OINTMENTS AND CREAMS 275 Preparatio
- Page 293 and 294:
OINTMENTS AND CREAMS 277 TABLE 3 Cr
- Page 295 and 296:
OINTMENTS AND CREAMS 279 FIGURE 1 S
- Page 297 and 298:
TABLE 4 Drug Acyclovir Alclometason
- Page 299 and 300:
OINTMENTS AND CREAMS 283 Packaging
- Page 301 and 302:
OINTMENTS AND CREAMS 285 presence o
- Page 303 and 304:
OINTMENTS AND CREAMS 287 side and s
- Page 305 and 306:
TABLE 6 a Drug Acyclovir Atropine s
- Page 307 and 308:
TABLE 7 Continued Commercial Produc
- Page 309 and 310:
GELS 293 (e.g., carbomers) that con
- Page 311 and 312:
GELS 295 molecular weight, gelling
- Page 313 and 314:
GELS 297 Ethylcellulose Ethylcellul
- Page 315 and 316:
GELS 299 practically insoluble in w
- Page 317 and 318:
GELS 301 out takes place. The visco
- Page 319 and 320:
GELS 303 FIGURE 3 Vacuum processing
- Page 321 and 322:
GELS 305 chramatograph for quantita
- Page 323 and 324:
TABLE 10 a Drug Benzocaine Benzoyl
- Page 325 and 326:
TABLE 11 Continued Type of Change C
- Page 327 and 328:
REFERENCES 311 8. Fisher , A. A. (
- Page 329 and 330:
4.3 LIQUID DOSAGE FORMS Maria V. Ru
- Page 331 and 332:
are both challenges and opportuniti
- Page 333 and 334:
GENERALITIES 317 that are more deci
- Page 335 and 336:
APPROACHES 319 To apply QbD as a sy
- Page 337 and 338:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 339 and 340:
Dosing Pumps Collector Tank Continu
- Page 341 and 342:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 343 and 344:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 345 and 346:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 347 and 348:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 349 and 350:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 351 and 352:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 353 and 354:
CRITICAL ASPECTS OF LIQUIDS MANUFAC
- Page 355 and 356:
LIQUID DOSAGE FORMS 339 For Solutio
- Page 357 and 358:
Suspension, Extended Release A liqu
- Page 359 and 360:
REFERENCES 343 26. Guides to inspec
- Page 361:
SECTION 5 SPECIAL/NEW DOSAGE FORMS
- Page 364 and 365:
348 CONTROLLED-RELEASE DOSAGE FORMS
- Page 366 and 367:
350 CONTROLLED-RELEASE DOSAGE FORMS
- Page 368 and 369:
352 CONTROLLED-RELEASE DOSAGE FORMS
- Page 370 and 371:
354 CONTROLLED-RELEASE DOSAGE FORMS
- Page 372 and 373:
356 CONTROLLED-RELEASE DOSAGE FORMS
- Page 374 and 375:
358 CONTROLLED-RELEASE DOSAGE FORMS
- Page 376 and 377:
360 CONTROLLED-RELEASE DOSAGE FORMS
- Page 378 and 379:
362 CONTROLLED-RELEASE DOSAGE FORMS
- Page 380 and 381:
364 CONTROLLED-RELEASE DOSAGE FORMS
- Page 382 and 383:
366 CONTROLLED-RELEASE DOSAGE FORMS
- Page 384 and 385:
368 CONTROLLED-RELEASE DOSAGE FORMS
- Page 386 and 387:
370 CONTROLLED-RELEASE DOSAGE FORMS
- Page 388 and 389:
372 CONTROLLED-RELEASE DOSAGE FORMS
- Page 390 and 391:
374 CONTROLLED-RELEASE DOSAGE FORMS
- Page 392 and 393:
376 CONTROLLED-RELEASE DOSAGE FORMS
- Page 394 and 395:
378 CONTROLLED-RELEASE DOSAGE FORMS
- Page 396 and 397:
380 CONTROLLED-RELEASE DOSAGE FORMS
- Page 398 and 399:
382 CONTROLLED-RELEASE DOSAGE FORMS
- Page 400 and 401:
384 CONTROLLED-RELEASE DOSAGE FORMS
- Page 402 and 403:
386 CONTROLLED-RELEASE DOSAGE FORMS
- Page 404 and 405:
388 CONTROLLED-RELEASE DOSAGE FORMS
- Page 406 and 407:
390 CONTROLLED-RELEASE DOSAGE FORMS
- Page 408 and 409:
392 CONTROLLED-RELEASE DOSAGE FORMS
- Page 410 and 411:
394 BIODEGRADABLE POLYMER-BASED MIC
- Page 412 and 413:
396 BIODEGRADABLE POLYMER-BASED MIC
- Page 414 and 415:
398 BIODEGRADABLE POLYMER-BASED MIC
- Page 416 and 417:
400 BIODEGRADABLE POLYMER-BASED MIC
- Page 418 and 419:
402 BIODEGRADABLE POLYMER-BASED MIC
- Page 420 and 421:
404 BIODEGRADABLE POLYMER-BASED MIC
- Page 422 and 423:
406 BIODEGRADABLE POLYMER-BASED MIC
- Page 424 and 425:
408 BIODEGRADABLE POLYMER-BASED MIC
- Page 426 and 427:
410 BIODEGRADABLE POLYMER-BASED MIC
- Page 428 and 429:
412 BIODEGRADABLE POLYMER-BASED MIC
- Page 430 and 431:
414 BIODEGRADABLE POLYMER-BASED MIC
- Page 432 and 433:
416 BIODEGRADABLE POLYMER-BASED MIC
- Page 434 and 435:
418 BIODEGRADABLE POLYMER-BASED MIC
- Page 436 and 437:
420 BIODEGRADABLE POLYMER-BASED MIC
- Page 438 and 439:
422 BIODEGRADABLE POLYMER-BASED MIC
- Page 440 and 441:
424 BIODEGRADABLE POLYMER-BASED MIC
- Page 442 and 443:
426 BIODEGRADABLE POLYMER-BASED MIC
- Page 444 and 445:
428 BIODEGRADABLE POLYMER-BASED MIC
- Page 446 and 447:
430 BIODEGRADABLE POLYMER-BASED MIC
- Page 448 and 449:
432 BIODEGRADABLE POLYMER-BASED MIC
- Page 450 and 451:
434 BIODEGRADABLE POLYMER-BASED MIC
- Page 452 and 453:
436 BIODEGRADABLE POLYMER-BASED MIC
- Page 454 and 455:
438 BIODEGRADABLE POLYMER-BASED MIC
- Page 456 and 457:
440 BIODEGRADABLE POLYMER-BASED MIC
- Page 459 and 460:
5.3 LIPOSOMES AND DRUG DELIVERY Sop
- Page 461 and 462:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 463 and 464:
H 2 C O O O - O - - O P O - O P O O
- Page 465 and 466:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 467 and 468:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 469 and 470:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 471 and 472:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 473 and 474:
In the second approach (probe sonic
- Page 475 and 476:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 477 and 478:
O R1 SH + N R2 N R2 R 1 Anchor R 2
- Page 479 and 480:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 481 and 482:
LIPOSOME STRUCTURE AND CHARACTERIST
- Page 483 and 484:
IN VIVO DISTRIBUTION 467 marrow (du
- Page 485 and 486:
IN VIVO DISTRIBUTION 469 absorption
- Page 487 and 488:
% injected dose/g % injected dose/g
- Page 489 and 490:
IN VIVO DISTRIBUTION 473 combinatio
- Page 491 and 492:
IN VIVO DISTRIBUTION 475 delivery i
- Page 493 and 494:
IN VIVO DISTRIBUTION 477 increases
- Page 495 and 496:
IN VIVO DISTRIBUTION 479 TABLE 3 Ex
- Page 497 and 498:
IN VIVO DISTRIBUTION 481 As mention
- Page 499 and 500:
TABLE 4 Currently Marketed Liposome
- Page 501 and 502:
addition to those existing already,
- Page 503 and 504:
Survival (%) 100 75 50 25 APPLICATI
- Page 505 and 506:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 507 and 508:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 509 and 510:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 511 and 512:
μg C 6 / MI Blood Ng C 6 / mg Tumo
- Page 513 and 514:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 515 and 516:
DXR plasma concentration (μg/mL) 1
- Page 517 and 518:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 519 and 520:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 521 and 522:
APPLICATIONS OF LIPOSOMES IN THERAP
- Page 523 and 524:
REFERENCES 507 6. Allen , T. M. , a
- Page 525 and 526:
REFERENCES 509 42. LeNeveu , D. M.
- Page 527 and 528:
REFERENCES 511 78. Frederik , P. M.
- Page 529 and 530:
REFERENCES 513 115. Grit , M. , de
- Page 531 and 532:
REFERENCES 515 154. Maruyama , K. ,
- Page 533 and 534:
REFERENCES 517 185. Schnyder , A. ,
- Page 535 and 536:
REFERENCES 519 220. Gregoriadis , G
- Page 537 and 538:
REFERENCES 521 254. Shek , P. N. ,
- Page 539 and 540:
REFERENCES 523 290. Weiner , N. , W
- Page 541 and 542:
REFERENCES 525 328. Torres , P. F.
- Page 543 and 544:
REFERENCES 527 A. ( 2004 ), Human i
- Page 545 and 546:
REFERENCES 529 393. Fiorillo , A. ,
- Page 547 and 548:
REFERENCES 531 423. Paridaens , R.
- Page 549:
REFERENCES 533 455. Seiden , M. V.
- Page 552 and 553:
536 BIODEGRADABLE NANOPARTICLES 5.4
- Page 554 and 555:
538 BIODEGRADABLE NANOPARTICLES Som
- Page 556 and 557:
540 BIODEGRADABLE NANOPARTICLES for
- Page 558 and 559:
542 BIODEGRADABLE NANOPARTICLES ami
- Page 560 and 561:
544 BIODEGRADABLE NANOPARTICLES bot
- Page 562 and 563:
546 BIODEGRADABLE NANOPARTICLES Pol
- Page 564 and 565:
548 BIODEGRADABLE NANOPARTICLES 99m
- Page 566 and 567:
550 BIODEGRADABLE NANOPARTICLES ext
- Page 568 and 569:
552 BIODEGRADABLE NANOPARTICLES 5.4
- Page 570 and 571:
554 BIODEGRADABLE NANOPARTICLES 14.
- Page 572 and 573:
556 BIODEGRADABLE NANOPARTICLES 48.
- Page 574 and 575:
558 BIODEGRADABLE NANOPARTICLES Cal
- Page 576 and 577:
560 BIODEGRADABLE NANOPARTICLES cop
- Page 578 and 579:
562 BIODEGRADABLE NANOPARTICLES 150
- Page 580 and 581:
564 BIODEGRADABLE NANOPARTICLES of
- Page 582 and 583:
566 IN VITRO VALIDATION AND ORAL FO
- Page 584 and 585:
568 IN VITRO VALIDATION AND ORAL FO
- Page 586 and 587:
570 IN VITRO VALIDATION AND ORAL FO
- Page 588 and 589:
572 IN VITRO VALIDATION AND ORAL FO
- Page 590 and 591:
574 IN VITRO VALIDATION AND ORAL FO
- Page 592 and 593:
576 IN VITRO VALIDATION AND ORAL FO
- Page 594 and 595:
578 IN VITRO VALIDATION AND ORAL FO
- Page 596 and 597:
580 IN VITRO VALIDATION AND ORAL FO
- Page 598 and 599:
582 IN VITRO VALIDATION AND ORAL FO
- Page 600 and 601:
584 IN VITRO VALIDATION AND ORAL FO
- Page 602 and 603:
586 IN VITRO VALIDATION AND ORAL FO
- Page 604 and 605:
588 IN VITRO VALIDATION AND ORAL FO
- Page 606 and 607:
590 IN VITRO VALIDATION AND ORAL FO
- Page 608 and 609:
592 NASAL DELIVERY OF PEPTIDE AND N
- Page 610 and 611:
594 NASAL DELIVERY OF PEPTIDE AND N
- Page 612 and 613:
596 NASAL DELIVERY OF PEPTIDE AND N
- Page 614 and 615:
598 NASAL DELIVERY OF PEPTIDE AND N
- Page 616 and 617:
600 NASAL DELIVERY OF PEPTIDE AND N
- Page 618 and 619:
602 NASAL DELIVERY OF PEPTIDE AND N
- Page 620 and 621:
604 NASAL DELIVERY OF PEPTIDE AND N
- Page 622 and 623:
606 NASAL DELIVERY OF PEPTIDE AND N
- Page 624 and 625:
608 NASAL DELIVERY OF PEPTIDE AND N
- Page 626 and 627:
610 NASAL DELIVERY OF PEPTIDE AND N
- Page 628 and 629:
612 NASAL DELIVERY OF PEPTIDE AND N
- Page 630 and 631:
614 NASAL DELIVERY OF PEPTIDE AND N
- Page 632 and 633:
616 NASAL DELIVERY OF PEPTIDE AND N
- Page 634 and 635:
618 NASAL DELIVERY OF PEPTIDE AND N
- Page 636 and 637:
620 NASAL DELIVERY OF PEPTIDE AND N
- Page 638 and 639:
622 NASAL DELIVERY OF PEPTIDE AND N
- Page 640 and 641:
624 NASAL DELIVERY OF PEPTIDE AND N
- Page 642 and 643:
626 NASAL DELIVERY OF PEPTIDE AND N
- Page 644 and 645:
628 NASAL DELIVERY OF PEPTIDE AND N
- Page 646 and 647:
630 NASAL DELIVERY OF PEPTIDE AND N
- Page 648 and 649:
632 NASAL DELIVERY OF PEPTIDE AND N
- Page 650 and 651:
634 NASAL DELIVERY OF PEPTIDE AND N
- Page 652 and 653:
636 NASAL DELIVERY OF PEPTIDE AND N
- Page 654 and 655:
638 NASAL DELIVERY OF PEPTIDE AND N
- Page 656 and 657:
640 NASAL DELIVERY OF PEPTIDE AND N
- Page 658 and 659:
642 NASAL DELIVERY OF PEPTIDE AND N
- Page 660 and 661:
644 NASAL DELIVERY OF PEPTIDE AND N
- Page 662 and 663:
646 NASAL DELIVERY OF PEPTIDE AND N
- Page 664 and 665:
648 NASAL DELIVERY OF PEPTIDE AND N
- Page 666 and 667:
650 NASAL DELIVERY OF PEPTIDE AND N
- Page 668 and 669:
652 NASAL POWDER DRUG DELIVERY clea
- Page 670 and 671:
654 NASAL POWDER DRUG DELIVERY cohe
- Page 672 and 673:
656 NASAL POWDER DRUG DELIVERY comb
- Page 674 and 675:
658 NASAL POWDER DRUG DELIVERY Its
- Page 676 and 677:
660 NASAL POWDER DRUG DELIVERY stud
- Page 678 and 679:
662 NASAL POWDER DRUG DELIVERY Chit
- Page 680 and 681:
664 NASAL POWDER DRUG DELIVERY PLGA
- Page 682 and 683:
666 NASAL POWDER DRUG DELIVERY ties
- Page 684 and 685:
668 NASAL POWDER DRUG DELIVERY [124
- Page 686 and 687:
TABLE 1 Continued Powder Formulatio
- Page 688 and 689:
TABLE 1 Continued Powder Formulatio
- Page 690 and 691:
674 NASAL POWDER DRUG DELIVERY REFE
- Page 692 and 693:
676 NASAL POWDER DRUG DELIVERY Drug
- Page 694 and 695:
678 NASAL POWDER DRUG DELIVERY 72.
- Page 696 and 697:
680 NASAL POWDER DRUG DELIVERY 109.
- Page 699 and 700:
5.8 AEROSOL DRUG DELIVERY Michael H
- Page 701 and 702:
HUMAN RESPIRATORY TRACT AND AEROSOL
- Page 703 and 704:
5.8.3 THERAPEUTIC INDICATIONS FOR A
- Page 705 and 706:
AEROSOL DRUG DELIVERY DEVICES 689 n
- Page 707 and 708:
FIGURE 1 Schematic of MDI. METERED
- Page 709 and 710:
TABLE 2 Property METERED DOSE INHAL
- Page 711 and 712:
METERED DOSE INHALERS 695 is then c
- Page 713 and 714:
METERED DOSE INHALERS 697 the other
- Page 715 and 716:
METERED DOSE INHALERS 699 the Easib
- Page 717 and 718:
5.8.6.2 Size Reduction and Particle
- Page 719 and 720:
DRY POWDER INHALERS 703 recognized
- Page 721 and 722:
DRY POWDER INHALERS 705 Spinhaler f
- Page 723 and 724:
oken up into droplets by the jet to
- Page 725 and 726:
EMERGING TECHNOLOGIES 709 Mouthpiec
- Page 727 and 728:
capillary, the formulation is rapid
- Page 729 and 730:
REFERENCES 713 22. Kim , C. S. , an
- Page 731 and 732:
REFERENCES 715 61. Blanchard , J. D
- Page 733 and 734:
REFERENCES 717 100. Dolovich , M. B
- Page 735 and 736:
REFERENCES 719 136. Anonymous ( 200
- Page 737 and 738:
REFERENCES 721 170. Ward , G. H. ,
- Page 739 and 740:
REFERENCES 723 206. Young , P. M. ,
- Page 741 and 742:
REFERENCES 725 244. DeFronzo , R. A
- Page 743:
REFERENCES 727 280. Schurmann , W.
- Page 746 and 747:
730 OCULAR DRUG DELIVERY tissues. T
- Page 748 and 749:
732 OCULAR DRUG DELIVERY FIGURE 3 S
- Page 750 and 751:
734 OCULAR DRUG DELIVERY melanocyte
- Page 752 and 753:
736 OCULAR DRUG DELIVERY represents
- Page 754 and 755:
738 OCULAR DRUG DELIVERY TABLE 1 Su
- Page 756 and 757:
740 OCULAR DRUG DELIVERY TABLE 1 Co
- Page 758 and 759:
742 OCULAR DRUG DELIVERY TABLE 2 Ma
- Page 760 and 761:
744 OCULAR DRUG DELIVERY shear - th
- Page 762 and 763:
746 OCULAR DRUG DELIVERY 5.9.3.3 Co
- Page 764 and 765:
748 OCULAR DRUG DELIVERY tigated in
- Page 766 and 767:
750 OCULAR DRUG DELIVERY that w/o M
- Page 768 and 769:
752 OCULAR DRUG DELIVERY [138, 232]
- Page 770 and 771:
754 OCULAR DRUG DELIVERY Only a few
- Page 772 and 773:
756 OCULAR DRUG DELIVERY 32. Schoen
- Page 774 and 775:
758 OCULAR DRUG DELIVERY 70. Shibuy
- Page 776 and 777:
760 OCULAR DRUG DELIVERY 105. Diepo
- Page 778 and 779:
762 OCULAR DRUG DELIVERY 139. Maest
- Page 780 and 781:
764 OCULAR DRUG DELIVERY 175. Davie
- Page 782 and 783:
766 OCULAR DRUG DELIVERY 213. Law ,
- Page 785 and 786:
5.10 MICROEMULSIONS AS DRUG DELIVER
- Page 787 and 788:
STRUCTURE AND FORMATION OF MICROEMU
- Page 789 and 790:
oily phase, and the interfacial lay
- Page 791 and 792:
CHARACTERIZE MICROEMULSIONS AND REL
- Page 793 and 794:
CHARACTERIZE MICROEMULSIONS AND REL
- Page 795 and 796:
study was conducted on systems comp
- Page 797 and 798:
5.10.6.1 Oral Drug Delivery MICROEM
- Page 799 and 800:
MICROEMULSIONS AS DRUG DELIVERY SYS
- Page 801 and 802:
REFERENCES 785 stability of incorpo
- Page 803 and 804:
REFERENCES 787 22. Saint - Ruth , H
- Page 805 and 806:
REFERENCES 789 58. Ktistis , G. ( 1
- Page 807 and 808:
REFERENCES 791 94. Rhee , Y. S. , C
- Page 809 and 810:
5.11 TRANSDERMAL DRUG DELIVERY C. S
- Page 811 and 812:
Drug plasma concentration FIGURE 1
- Page 813 and 814:
PHYSIOLOGY AND CHARACTERISTICS OF H
- Page 815 and 816:
Another important parameter when se
- Page 817 and 818:
COMMERCIALLY AVAILABLE PATCHES 801
- Page 819 and 820:
5.11.8.1 Chemical Penetration Enhan
- Page 821 and 822:
corneum much like the microneedle t
- Page 823:
REFERENCES 807 40. Mitragotri , S.
- Page 826 and 827:
810 VAGINAL DRUG DELIVERY 5.12.5.6
- Page 828 and 829:
812 VAGINAL DRUG DELIVERY The vagin
- Page 830 and 831:
814 VAGINAL DRUG DELIVERY have mucu
- Page 832 and 833:
816 VAGINAL DRUG DELIVERY TABLE 1 C
- Page 834 and 835:
818 VAGINAL DRUG DELIVERY Menopausa
- Page 836 and 837:
820 VAGINAL DRUG DELIVERY 500 400 3
- Page 838 and 839:
822 VAGINAL DRUG DELIVERY spreadabi
- Page 840 and 841:
824 VAGINAL DRUG DELIVERY distribut
- Page 842 and 843:
826 VAGINAL DRUG DELIVERY improved
- Page 844 and 845:
828 VAGINAL DRUG DELIVERY FIGURE 4
- Page 846 and 847:
830 VAGINAL DRUG DELIVERY FIGURE 6
- Page 848 and 849:
832 VAGINAL DRUG DELIVERY 5.12.4.10
- Page 850 and 851:
834 VAGINAL DRUG DELIVERY availabil
- Page 852 and 853:
836 VAGINAL DRUG DELIVERY 5.12.4.12
- Page 854 and 855:
838 VAGINAL DRUG DELIVERY results.
- Page 856 and 857:
840 VAGINAL DRUG DELIVERY 5.12.5.6
- Page 858 and 859:
842 VAGINAL DRUG DELIVERY studies t
- Page 860 and 861:
844 VAGINAL DRUG DELIVERY subject i
- Page 862 and 863:
846 VAGINAL DRUG DELIVERY formulati
- Page 864 and 865:
848 VAGINAL DRUG DELIVERY FIGURE 8
- Page 866 and 867:
850 VAGINAL DRUG DELIVERY shown to
- Page 868 and 869:
852 VAGINAL DRUG DELIVERY poloxamer
- Page 870 and 871:
854 VAGINAL DRUG DELIVERY made. Ide
- Page 872 and 873:
856 VAGINAL DRUG DELIVERY FIGURE 9
- Page 874 and 875:
858 VAGINAL DRUG DELIVERY 13. Wagne
- Page 876 and 877:
860 VAGINAL DRUG DELIVERY 54. Corbo
- Page 878 and 879:
862 VAGINAL DRUG DELIVERY supposito
- Page 880 and 881:
864 VAGINAL DRUG DELIVERY 123. van
- Page 882 and 883:
866 VAGINAL DRUG DELIVERY nanospher
- Page 884 and 885:
868 VAGINAL DRUG DELIVERY 196. Jone
- Page 886 and 887:
870 VAGINAL DRUG DELIVERY Irritatio
- Page 888 and 889:
872 VAGINAL DRUG DELIVERY 261. Czei
- Page 890 and 891:
874 VAGINAL DRUG DELIVERY 293. Fowl
- Page 892 and 893:
876 VAGINAL DRUG DELIVERY 327. O
- Page 894 and 895:
878 VAGINAL DRUG DELIVERY 359. Rath
- Page 897 and 898:
6.1 PHARMACEUTICAL PREFORMULATION:
- Page 899 and 900:
tion. According to global Internati
- Page 901 and 902:
SELECTION OF PHARMACEUTICAL EXCIPIE
- Page 903 and 904:
SELECTION OF PHARMACEUTICAL EXCIPIE
- Page 905 and 906:
TABLE 4 Disintegrant Starch Commonl
- Page 907 and 908:
SELECTION OF PHARMACEUTICAL EXCIPIE
- Page 909 and 910:
SELECTION OF PHARMACEUTICAL EXCIPIE
- Page 911 and 912:
SELECTION OF PHARMACEUTICAL EXCIPIE
- Page 913 and 914:
DRUG-EXCIPIENT COMPATIBILITY 897 ap
- Page 915 and 916:
DRUG-EXCIPIENT COMPATIBILITY 899 in
- Page 917 and 918:
POWDER CHARACTERISTICS 901 their im
- Page 919 and 920:
POWDER CHARACTERISTICS 903 TABLE 13
- Page 921 and 922:
POWDER CHARACTERISTICS 905 Microsco
- Page 923 and 924:
Powder flow rate FIGURE 6 No flow b
- Page 925 and 926:
POWDER CHARACTERISTICS 909 Measurem
- Page 927 and 928:
V − V ε= V b p b V = 1− V POWD
- Page 929 and 930:
POWDER CHARACTERISTICS 913 The mois
- Page 931 and 932:
Tensile strength (Pa) 14 12 10 8 6
- Page 933 and 934:
POWDER CHARACTERISTICS 917 and poor
- Page 935 and 936:
infl uence the physicochemical prop
- Page 937 and 938:
Tablet disintegration is the import
- Page 939 and 940:
ability studies and from human stud
- Page 941 and 942:
Variables Affecting Dissolution In
- Page 943 and 944:
TABLET CHARACTERIZATION 927 The dif
- Page 945 and 946:
The requirements for content unifor
- Page 947:
REFERENCES 931 15. Simon , P. , Vev
- Page 950 and 951:
934 ROLE OF PREFORMULATION IN DEVEL
- Page 952 and 953:
936 ROLE OF PREFORMULATION IN DEVEL
- Page 954 and 955:
938 ROLE OF PREFORMULATION IN DEVEL
- Page 956 and 957:
940 ROLE OF PREFORMULATION IN DEVEL
- Page 958 and 959:
942 ROLE OF PREFORMULATION IN DEVEL
- Page 960 and 961:
944 ROLE OF PREFORMULATION IN DEVEL
- Page 962 and 963:
946 ROLE OF PREFORMULATION IN DEVEL
- Page 964 and 965:
948 ROLE OF PREFORMULATION IN DEVEL
- Page 966 and 967:
950 ROLE OF PREFORMULATION IN DEVEL
- Page 968 and 969:
952 ROLE OF PREFORMULATION IN DEVEL
- Page 970 and 971:
954 ROLE OF PREFORMULATION IN DEVEL
- Page 972 and 973:
956 ROLE OF PREFORMULATION IN DEVEL
- Page 974 and 975:
958 ROLE OF PREFORMULATION IN DEVEL
- Page 976 and 977:
960 ROLE OF PREFORMULATION IN DEVEL
- Page 978 and 979:
962 ROLE OF PREFORMULATION IN DEVEL
- Page 980 and 981:
964 ROLE OF PREFORMULATION IN DEVEL
- Page 982 and 983:
966 ROLE OF PREFORMULATION IN DEVEL
- Page 984 and 985:
968 ROLE OF PREFORMULATION IN DEVEL
- Page 986 and 987:
970 ROLE OF PREFORMULATION IN DEVEL
- Page 988 and 989:
972 ROLE OF PREFORMULATION IN DEVEL
- Page 990 and 991:
974 ROLE OF PREFORMULATION IN DEVEL
- Page 993 and 994:
6.3 TABLET DESIGN Eddy Castellanos
- Page 995 and 996:
TABLETING CYCLE 979 The eccentric p
- Page 997 and 998:
FIGURE 4 (a) (b) (c) TABLETING CYCL
- Page 999 and 1000:
TABLE 1 mm 3 4 5 6 7 8 9 10 11 12 1
- Page 1001 and 1002:
LIMITATIONS FOR DIRECT COMPRESSION
- Page 1003 and 1004:
Drug release (%) 120 100 80 60 40 2
- Page 1005 and 1006:
Beta Carotene Tablets (15 mg ) Form
- Page 1007 and 1008:
Lisinopril release (%) FIGURE 10 BI
- Page 1009 and 1010:
that do not compress well after wet
- Page 1011 and 1012:
Calcium phosphate, dibasic offers h
- Page 1013 and 1014:
FIGURE 11 Theophylline release (%)
- Page 1015 and 1016:
TABLET DESIGN WITH NATURAL PRODUCTS
- Page 1017 and 1018:
TABLE 7 Two Formulations for mangif
- Page 1019 and 1020:
TABLE 8 Weight Assay Disintegration
- Page 1021 and 1022:
TABLET DESIGN WITH NATURAL PRODUCTS
- Page 1023 and 1024:
has a regulatory effect upon the an
- Page 1025 and 1026:
DESIGN TOOLS OF TABLET FORMULATION
- Page 1027 and 1028:
Amount released PPL (%) 110 100 90
- Page 1029 and 1030:
DESIGN TOOLS OF TABLET FORMULATION
- Page 1031 and 1032:
Percolation threshold (ε c) FIGURE
- Page 1033 and 1034:
6.3.8 COATING SYSTEMS COATING SYSTE
- Page 1035 and 1036:
COATING SYSTEMS 1019 ences between
- Page 1037 and 1038:
Water absorption, % 8 7 6 5 4 3 2 1
- Page 1039 and 1040:
FIGURE 28 white. mg/h·m 0.9 0.8 0.
- Page 1041 and 1042:
(a) (b) FIGURE 31 ( a ) Tablet coat
- Page 1043 and 1044:
TABLE 18 Solid content Batch size,
- Page 1045 and 1046:
Percent released FIGURE 35 Tablet b
- Page 1047 and 1048:
PHARMACEUTICAL TABLETS USING PERCOL
- Page 1049 and 1050:
TABLE 23 Calculation of Tablet Prop
- Page 1051 and 1052:
PHARMACEUTICAL TABLETS USING PERCOL
- Page 1053 and 1054:
PHARMACEUTICAL TABLETS USING PERCOL
- Page 1055 and 1056:
TABLE 25 Aspect Ratios and Exponent
- Page 1057 and 1058:
K H (%min - 1/2)/% v/v excipient pl
- Page 1059 and 1060:
6.3.10 ULTRASOUND-ASSISTED TABLETIN
- Page 1061 and 1062:
ULTRASOUND-ASSISTED TABLETING (A NE
- Page 1063 and 1064:
REFERENCES 1047 18. S á nchez , G.
- Page 1065 and 1066:
REFERENCES 1049 54. Hess , H. , and
- Page 1067:
92. Mill á n , M. , and Caraballo
- Page 1070 and 1071:
1054 TABLET PRODUCTION SYSTEMS 6.4.
- Page 1072 and 1073:
1056 TABLET PRODUCTION SYSTEMS comp
- Page 1074 and 1075:
1058 TABLET PRODUCTION SYSTEMS and
- Page 1076 and 1077:
1060 TABLET PRODUCTION SYSTEMS FIGU
- Page 1078 and 1079:
1062 TABLET PRODUCTION SYSTEMS FIGU
- Page 1080 and 1081:
1064 TABLET PRODUCTION SYSTEMS FIGU
- Page 1082 and 1083:
1066 TABLET PRODUCTION SYSTEMS when
- Page 1084 and 1085:
1068 TABLET PRODUCTION SYSTEMS die
- Page 1086 and 1087:
1070 TABLET PRODUCTION SYSTEMS FIGU
- Page 1088 and 1089:
1072 TABLET PRODUCTION SYSTEMS TABL
- Page 1090 and 1091:
1074 TABLET PRODUCTION SYSTEMS Pres
- Page 1092 and 1093:
1076 TABLET PRODUCTION SYSTEMS Forc
- Page 1094 and 1095:
1078 TABLET PRODUCTION SYSTEMS In(1
- Page 1096 and 1097:
1080 TABLET PRODUCTION SYSTEMS In[1
- Page 1098 and 1099:
1082 TABLET PRODUCTION SYSTEMS [78,
- Page 1100 and 1101:
1084 TABLET PRODUCTION SYSTEMS FIGU
- Page 1102 and 1103:
1086 TABLET PRODUCTION SYSTEMS When
- Page 1104 and 1105:
1088 TABLET PRODUCTION SYSTEMS 3. P
- Page 1106 and 1107:
1090 TABLET PRODUCTION SYSTEMS 44.
- Page 1108 and 1109:
1092 TABLET PRODUCTION SYSTEMS 81.
- Page 1110 and 1111:
1094 TABLET PRODUCTION SYSTEMS 119.
- Page 1112 and 1113:
1096 TABLET PRODUCTION SYSTEMS 160.
- Page 1114 and 1115:
1098 TABLET PRODUCTION SYSTEMS 197.
- Page 1116 and 1117:
1100 CONTROLLED RELEASE OF DRUGS FR
- Page 1118 and 1119:
1102 CONTROLLED RELEASE OF DRUGS FR
- Page 1120 and 1121:
1104 CONTROLLED RELEASE OF DRUGS FR
- Page 1122 and 1123:
1106 CONTROLLED RELEASE OF DRUGS FR
- Page 1124 and 1125:
1108 CONTROLLED RELEASE OF DRUGS FR
- Page 1126 and 1127:
1110 CONTROLLED RELEASE OF DRUGS FR
- Page 1128 and 1129:
1112 CONTROLLED RELEASE OF DRUGS FR
- Page 1130 and 1131:
1114 CONTROLLED RELEASE OF DRUGS FR
- Page 1132 and 1133:
1116 CONTROLLED RELEASE OF DRUGS FR
- Page 1134 and 1135:
1118 CONTROLLED RELEASE OF DRUGS FR
- Page 1136 and 1137:
1120 CONTROLLED RELEASE OF DRUGS FR
- Page 1138 and 1139:
1122 CONTROLLED RELEASE OF DRUGS FR
- Page 1140 and 1141:
1124 CONTROLLED RELEASE OF DRUGS FR
- Page 1142 and 1143:
1126 CONTROLLED RELEASE OF DRUGS FR
- Page 1144 and 1145:
1128 CONTROLLED RELEASE OF DRUGS FR
- Page 1146 and 1147:
1130 CONTROLLED RELEASE OF DRUGS FR
- Page 1148 and 1149:
1132 CONTROLLED RELEASE OF DRUGS FR
- Page 1150 and 1151:
1134 TABLET COMPRESSION stages invo
- Page 1152 and 1153:
1136 TABLET COMPRESSION although on
- Page 1154 and 1155:
1138 TABLET COMPRESSION P P = + C a
- Page 1156 and 1157:
1140 TABLET COMPRESSION 4. Estimati
- Page 1158 and 1159:
1142 TABLET COMPRESSION from a hopp
- Page 1160 and 1161:
1144 TABLET COMPRESSION speed of th
- Page 1162 and 1163:
1146 TABLET COMPRESSION FIGURE 4 Co
- Page 1164 and 1165:
1148 TABLET COMPRESSION FIGURE 5 Id
- Page 1166 and 1167:
1150 TABLET COMPRESSION its low tou
- Page 1168 and 1169:
1152 TABLET COMPRESSION Standard TS
- Page 1170 and 1171:
1154 TABLET COMPRESSION A B C D E F
- Page 1172 and 1173:
1156 TABLET COMPRESSION Top view Pr
- Page 1174 and 1175:
1158 TABLET COMPRESSION particle si
- Page 1176 and 1177:
1160 TABLET COMPRESSION 6.6.10.3 Mo
- Page 1178 and 1179:
1162 TABLET COMPRESSION 7. Masteau
- Page 1181 and 1182:
6.7 EFFECTS OF GRINDING IN PHARMACE
- Page 1183 and 1184:
MILLING EQUIPMENT 1167 whereas smal
- Page 1185 and 1186:
Screen Product FIGURE 3 Hammers Ham
- Page 1187 and 1188:
inders, disintegrants, glidants, lu
- Page 1189 and 1190:
Airflow Press POWDER CHARACTERIZATI
- Page 1191 and 1192:
Powder flow Sample Process stream (
- Page 1193 and 1194:
Container 1 Container 1 Discard (a)
- Page 1195 and 1196:
Porous particles in container POWDE
- Page 1197 and 1198:
POWDER CHARACTERIZATION TECHNIQUES
- Page 1199 and 1200:
expansions or fractal dimensions);
- Page 1201 and 1202:
EFFECT OF PARTICLE SIZE REDUCTION O
- Page 1203 and 1204:
EFFECT OF PARTICLE SIZE REDUCTION O
- Page 1205 and 1206:
REFERENCES 1189 19. British Standar
- Page 1207 and 1208:
6.8 ORAL EXTENDED - RELEASE FORMULA
- Page 1209 and 1210:
INTRODUCTION 1193 line) together wi
- Page 1211 and 1212:
INTRODUCTION 1195 substance) instea
- Page 1213 and 1214:
of the drug particles/formulation a
- Page 1215 and 1216:
M A DCt t = ⎡ ε s ( 2C − C )
- Page 1217 and 1218:
method for insoluble matrix tablets
- Page 1219 and 1220:
MEMBRANE-COATED ORAL EXTENDED RELEA
- Page 1221 and 1222:
MEMBRANE-COATED ORAL EXTENDED RELEA
- Page 1223 and 1224:
Swelling front Diffusion front Eros
- Page 1225 and 1226:
dM Q = ∫ dt = kt 0 dt HYDROPHILIC
- Page 1227 and 1228:
TABLE 2 FDA Registered Oral ER Form
- Page 1229 and 1230:
6.8.6 OTHER ORAL ER FORMULATIONS OT
- Page 1231 and 1232:
REFERENCES 1215 15. Neau , S. H. ,
- Page 1233 and 1234:
REFERENCES 1217 54. Sousa , J. J. ,
- Page 1235 and 1236:
REFERENCES 1219 89. Ford , J. L. ,
- Page 1237 and 1238:
REFERENCES 1221 122. Talukdar , M.
- Page 1239:
SECTION 7 ROLE OF NANOTECHNOLOGY
- Page 1242 and 1243:
1226 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1244 and 1245:
1228 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1246 and 1247:
1230 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1248 and 1249:
1232 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1250 and 1251:
1234 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1252 and 1253:
1236 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1254 and 1255:
1238 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1256 and 1257:
1240 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1258 and 1259:
1242 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1260 and 1261:
1244 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1262 and 1263:
1246 CYCLODEXTRIN-BASED NANOMATERIA
- Page 1265 and 1266:
7.2 NANOTECHNOLOGY IN PHARMACEUTICA
- Page 1267 and 1268:
NANOMATERIALS 1251 tists regard mat
- Page 1269 and 1270:
NANOMATERIALS 1253 TABLE 1 Characte
- Page 1271 and 1272:
NANOMATERIALS 1255 sor molecules/pa
- Page 1273 and 1274:
TABLE 2 Continued Types of Nanomate
- Page 1275 and 1276:
H 3 C CH 3 N + CH 3 O O O O - P O O
- Page 1277 and 1278:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1279 and 1280:
entrapped drugs releasing [90] . So
- Page 1281 and 1282:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1283 and 1284:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1285 and 1286:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1287 and 1288:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1289 and 1290:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1291 and 1292:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1293 and 1294:
NANOTECHNOLOGY FOR DRUG DELIVERY 12
- Page 1295 and 1296:
NANOMEDICINE 1279 prises) visibly p
- Page 1297 and 1298:
REFERENCES 1281 16. http://www.whit
- Page 1299 and 1300:
REFERENCES 1283 55. Kam , N. W. S.
- Page 1301 and 1302:
REFERENCES 1285 92. Zhang , J. Q. ,
- Page 1303 and 1304:
REFERENCES 1287 126. Smart , S. K.
- Page 1305 and 1306:
7.3 PHARMACEUTICAL NANOSYSTEMS: MAN
- Page 1307 and 1308:
7.3.2 TAXONOMY OF NANOMEDICINE TECH
- Page 1309 and 1310:
TABLE 1 Continued Molecular medicin
- Page 1311 and 1312:
Applications of quantum dots includ
- Page 1313 and 1314:
7.3.5 MANUFACTURING TECHNOLOGIES Th
- Page 1315 and 1316:
Ratio of hydrodynamic radius, R H ,
- Page 1317 and 1318:
eplicated on the substrate, with na
- Page 1319 and 1320:
MANUFACTURING TECHNOLOGIES 1303 bel
- Page 1321 and 1322:
CHARACTERIZATION TECHNIQUES 1305 TA
- Page 1323 and 1324:
CHARACTERIZATION TECHNIQUES 1307 TA
- Page 1325 and 1326:
Limitations of AFM [255 - 257] Pote
- Page 1327 and 1328:
REFERENCES 1311 thelial cells, the
- Page 1329 and 1330:
REFERENCES 1313 34. Ostrander , K.
- Page 1331 and 1332:
REFERENCES 1315 77. Muangsiri , W.
- Page 1333 and 1334:
REFERENCES 1317 124. Caruso , F. ,
- Page 1335 and 1336:
REFERENCES 1319 170. Rogers , J. A.
- Page 1337 and 1338:
REFERENCES 1321 application: Synthe
- Page 1339 and 1340:
252. Fontaine , P. A. , et al. ( 19
- Page 1341:
Characterization Methods Binks , B.
- Page 1344 and 1345:
1328 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1346 and 1347:
1330 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1348 and 1349:
1332 Application TABLE 1 Selected M
- Page 1350 and 1351:
1334 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1352 and 1353:
1336 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1354 and 1355:
1338 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1356 and 1357:
1340 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1358 and 1359:
1342 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1360 and 1361:
1344 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1362 and 1363:
1346 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1364 and 1365:
1348 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1366 and 1367:
1350 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1368 and 1369:
1352 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1370 and 1371:
1354 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1372 and 1373:
1356 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1374 and 1375:
1358 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1376 and 1377:
1360 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1378 and 1379:
1362 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1380 and 1381:
1364 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1382 and 1383:
1366 OIL-IN-WATER NANOSIZED EMULSIO
- Page 1384 and 1385:
1368 INDEX Cholera toxin, 637 Cilio
- Page 1386:
1370 INDEX Production of radiopharm
Inappropriate
Loading...
Inappropriate
You have already flagged this document.
Thank you, for helping us keep this platform clean.
The editors will have a look at it as soon as possible.
Mail this publication
Loading...
Embed
Loading...
Delete template?
Are you sure you want to delete your template?
DOWNLOAD ePAPER
This ePaper is currently not available for download.
You can find similar magazines on this topic below under ‘Recommendations’.